| pubmed-article:10221683 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10221683 | lifeskim:mentions | umls-concept:C0031327 | lld:lifeskim |
| pubmed-article:10221683 | lifeskim:mentions | umls-concept:C0033308 | lld:lifeskim |
| pubmed-article:10221683 | lifeskim:mentions | umls-concept:C0376315 | lld:lifeskim |
| pubmed-article:10221683 | lifeskim:mentions | umls-concept:C1521801 | lld:lifeskim |
| pubmed-article:10221683 | lifeskim:mentions | umls-concept:C0205296 | lld:lifeskim |
| pubmed-article:10221683 | lifeskim:mentions | umls-concept:C0042264 | lld:lifeskim |
| pubmed-article:10221683 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:10221683 | pubmed:dateCreated | 1999-6-10 | lld:pubmed |
| pubmed-article:10221683 | pubmed:abstractText | Our study was conducted to assess the pharmacokinetics of natural progesterone administered in the novel formula of an effervescent vaginal tablet. Fifty post-menopausal women, with a median age of 43.5 years (range 28-55), volunteered to participate in the research. All women discontinued their hormonal replacement therapy 1 month prior to the study. The pharmacokinetics of 50 and 100 mg of progesterone administered as a vaginal tablet were evaluated. After the initial administration of 50 mg or 100 mg, a mean serum Cmax of 20.43 +/- 8.01 nmol/l and 31.61 +/- 12.62 nmol/l (P < 0.0004) was reached at a Tmax of 6.1 +/- 2.63 and 6.4 +/- 3.35 h respectively. The terminal half-life was 13.18 +/- 1.3 and 13.7 +/- 1.05 h respectively. Continuous use of the 100-mg tablet resulted in a mean serum progesterone concentration of 26.08 +/- 13.96 nmol/l and 21.42 +/- 16.32 nmol/l after 14 and 30 days respectively. Women >40 years were found to have a significantly lower Tmax compared to younger women (P = 0.02). The continuous use of vaginal progesterone did not influence the hormonal, liver or lipid profiles evaluated. Only three (6%) women suffered from mild vaginal irritation. Natural progesterone given as a vaginal tablet is well tolerated, safe and an easily administered treatment. Even in a non-oestrogenized vagina the absorption was efficient and the 100 mg dosage resulted in adequate serum progesterone concentrations. | lld:pubmed |
| pubmed-article:10221683 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10221683 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10221683 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:10221683 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10221683 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10221683 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10221683 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:10221683 | pubmed:issn | 0268-1161 | lld:pubmed |
| pubmed-article:10221683 | pubmed:author | pubmed-author:HomburgRR | lld:pubmed |
| pubmed-article:10221683 | pubmed:author | pubmed-author:MagazanikAA | lld:pubmed |
| pubmed-article:10221683 | pubmed:author | pubmed-author:LeviDD | lld:pubmed |
| pubmed-article:10221683 | pubmed:author | pubmed-author:AshkenaziJJ | lld:pubmed |
| pubmed-article:10221683 | pubmed:author | pubmed-author:Ben-RafaelZZ | lld:pubmed |
| pubmed-article:10221683 | pubmed:author | pubmed-author:Bar-HavaII | lld:pubmed |
| pubmed-article:10221683 | pubmed:author | pubmed-author:OrvietoRR | lld:pubmed |
| pubmed-article:10221683 | pubmed:author | pubmed-author:GurevitchSS | lld:pubmed |
| pubmed-article:10221683 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10221683 | pubmed:volume | 14 | lld:pubmed |
| pubmed-article:10221683 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10221683 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10221683 | pubmed:pagination | 606-10 | lld:pubmed |
| pubmed-article:10221683 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:10221683 | pubmed:meshHeading | pubmed-meshheading:10221683... | lld:pubmed |
| pubmed-article:10221683 | pubmed:meshHeading | pubmed-meshheading:10221683... | lld:pubmed |
| pubmed-article:10221683 | pubmed:meshHeading | pubmed-meshheading:10221683... | lld:pubmed |
| pubmed-article:10221683 | pubmed:meshHeading | pubmed-meshheading:10221683... | lld:pubmed |
| pubmed-article:10221683 | pubmed:meshHeading | pubmed-meshheading:10221683... | lld:pubmed |
| pubmed-article:10221683 | pubmed:meshHeading | pubmed-meshheading:10221683... | lld:pubmed |
| pubmed-article:10221683 | pubmed:meshHeading | pubmed-meshheading:10221683... | lld:pubmed |
| pubmed-article:10221683 | pubmed:meshHeading | pubmed-meshheading:10221683... | lld:pubmed |
| pubmed-article:10221683 | pubmed:meshHeading | pubmed-meshheading:10221683... | lld:pubmed |
| pubmed-article:10221683 | pubmed:meshHeading | pubmed-meshheading:10221683... | lld:pubmed |
| pubmed-article:10221683 | pubmed:meshHeading | pubmed-meshheading:10221683... | lld:pubmed |
| pubmed-article:10221683 | pubmed:meshHeading | pubmed-meshheading:10221683... | lld:pubmed |
| pubmed-article:10221683 | pubmed:year | 1999 | lld:pubmed |
| pubmed-article:10221683 | pubmed:articleTitle | Pharmacokinetics of natural progesterone administered in the form of a vaginal tablet. | lld:pubmed |
| pubmed-article:10221683 | pubmed:affiliation | Department of Obstetrics and Gynecology, Rabin Medical Center, Petah Tikva, Israel. | lld:pubmed |
| pubmed-article:10221683 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:10221683 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10221683 | lld:pubmed |
